Orum Therapeutics, Inc. Stock Price

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases in South Korea and the United States. The company develops ORM-6151, which is in Phase I clinical trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes; ORM-1153, which is in pre-clinical trial for the treatment of acute myeloid leukemia and hematologic malignancies; and ORM-1023, which is in pre-clinical trial for the treatment of small cell lung cancer and neuroendocrine tumor. It is also involved in the development of multiple programs for the treatment of solid tumors and immunology and inflammation; and E3 Ligase-DAC adaptor, an adaptor linker platform that conjugates protein degraders to antibodies and enables E3 ligase-based DACs. The company was founded in 2016 and is headquartered in Daejeon, South Korea.